Mucolytic action

"Mucolytic action" describes the process by which certain drugs reduce the viscosity and stickiness of mucus in the respiratory tract, making it easier to clear from the airways. This is achieved by breaking down chemical bonds within mucus molecules—most commonly disulfide bonds in mucin proteins—or by enzymatically degrading extracellular DNA that contributes to mucus thickness. Mucolytics are used primarily for chronic lung diseases such as cystic fibrosis, COPD, and bronchiectasis. They are not themselves molecular targets but rather describe an effect produced by various agents acting on different components of airway secretions[1][2][3][6]. Note: "Mucolytic action" is not a canonical name for any molecule or receptor; it refers broadly to a pharmacologic mechanism shared by several drug classes and agents. It should not be treated as a discrete biological target for structured data purposes.

Breaks disulfide bonds in mucin proteins (e.g., acetylcysteine); Acts as a recombinant human DNase to degrade DNA in mucus (e.g., dornase alfa); Restores balance of mucins and reduces viscosity (e.g., carbocisteine).